Applied Therapeutics Stock

Applied Therapeutics ROCE 2024

Applied Therapeutics ROCE

3.76

Ticker

APLT

ISIN

US03828A1016

WKN

A2PHHB

In 2024, Applied Therapeutics's return on capital employed (ROCE) was 3.76, a -118.6% increase from the -20.23 ROCE in the previous year.

Applied Therapeutics Aktienanalyse

What does Applied Therapeutics do?

Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for chronic and specific serious diseases. The company was founded in 2016 by Shoshana Shendelman, who is also the CEO of the company. Applied Therapeutics is headquartered in New York City and currently employs over 50 employees. The business model of Applied Therapeutics is designed to address gaps in current medical care and develop novel therapies that do not yet exist. The company invests heavily in research and development to find new drugs and therapies that are more effective and safer than existing treatment methods. Applied Therapeutics has focused on developing drugs that can be used in the areas of neurological and cardiovascular diseases, as well as metabolic diseases. The main products currently under development aim to treat metabolic diseases such as diabetic neuropathy and mucopolysaccharidosis (MPS). The company has a broad portfolio of technologies, including the targeted protein degrader platform, which aims to degrade critical proteins that play a role in certain diseases. Applied Therapeutics also uses genomics to gain a deeper understanding of the underlying causes of diseases. By identifying targets for new drugs and therapies, the company also uses AI algorithms to select promising candidates for clinical trials. Applied Therapeutics' particular expertise lies in the research of molecules that play a key role in regulating carbohydrate metabolism and energy production in the body. Applied Therapeutics' medications aim to selectively regulate these critical molecules and thus combat various diseases. The first product from Applied Therapeutics is AT-001, a medication for the treatment of diabetic neuropathies. A phase II study has shown that AT-001 provides a significant improvement in neuropathic pain and sensitivity. The medication is currently being tested in a phase III clinical trial. Another promising class of drugs from Applied Therapeutics is the SGLT2 inhibitor, which targets carbohydrate metabolism and thus covers a wide range of diseases, from diabetes to cardiovascular diseases. Applied Therapeutics has also signed a license agreement with the University of Minnesota for the development of medications for the treatment of MPS I. In this collaboration, the company brings its expertise in molecules regulating carbohydrate and energy metabolism to develop a new treatment for MPS patients. It is important to mention that Applied Therapeutics' drugs are still in development and are in various stages of clinical trials. After completing the clinical trials and potential FDA approval, the products must also be brought to market, which can pose additional challenges. Overall, Applied Therapeutics has focused on developing therapies for chronic and serious diseases. The company has a broad portfolio of technologies aimed at combating the underlying causes of diseases. With AT-001 already on the market, the company has brought a promising medication to market, and additional products are in development. Whether the company will meet its ambitious goals remains to be seen, but there is no doubt that it operates in an exciting area with great potential. Applied Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Applied Therapeutics's Return on Capital Employed (ROCE)

Applied Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Applied Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Applied Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Applied Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Applied Therapeutics stock

What is the ROCE (Return on Capital Employed) of Applied Therapeutics this year?

The ROCE of Applied Therapeutics is 3.76 undefined this year.

How has the ROCE (Return on Capital Employed) of Applied Therapeutics developed compared to the previous year?

The ROCE of Applied Therapeutics has increased by -118.6% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Applied Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Applied Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Applied Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Applied Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Applied Therapeutics impact the company?

An increase in the ROCE of Applied Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Applied Therapeutics affect the company?

A decrease in ROCE of Applied Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Applied Therapeutics?

Some factors that can affect Applied Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Applied Therapeutics so important for investors?

The ROCE of Applied Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Applied Therapeutics take to improve the ROCE?

To improve the ROCE, Applied Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Applied Therapeutics pay?

Over the past 12 months, Applied Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Applied Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Applied Therapeutics?

The current dividend yield of Applied Therapeutics is .

When does Applied Therapeutics pay dividends?

Applied Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Applied Therapeutics?

Applied Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Applied Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Applied Therapeutics located?

Applied Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Applied Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Applied Therapeutics from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Applied Therapeutics pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Applied Therapeutics in the year 2023?

In the year 2023, Applied Therapeutics distributed 0 USD as dividends.

In which currency does Applied Therapeutics pay out the dividend?

The dividends of Applied Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Applied Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Applied Therapeutics

Our stock analysis for Applied Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.